Evoke Pharma, Inc. (EVOK) Financial Ratios
14 years of historical data (2011–2024) · Healthcare · Drug Manufacturers - Specialty & Generic
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↓
2.98
+8% vs avg
5yr avg: 2.75
30Y Low0.8·High15.6
ROE
↑
-240.1%
↓+86% vs avg
5yr avg: -1752.5%
30Y Low-411%·High-87%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
EVOK Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Evoke Pharma, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $19M | $8M | $4M | $8M | $18M | $66M | $36M | $41M | $34M | $19M | $21M |
| Enterprise Value | $11M | $-15691 | $9M | $4M | $14M | $63M | $31M | $36M | $26M | $10M | $17M |
| P/E Ratio → | -3.91 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 1.85 | 0.82 | 0.68 | 3.36 | 10.94 | 2858.21 | — | — | — | — | — |
| P/B Ratio | 2.98 | 1.20 | — | 2.06 | 4.98 | — | 8.25 | 10.23 | 15.55 | 4.98 | 6.18 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
EVOK EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | -0.00 | 1.69 | 1.48 | 8.39 | 2735.57 | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
EVOK Profitability
Margins and return-on-capital ratios measuring operating efficiency
Evoke Pharma, Inc. earns an operating margin of -50.8%. Operating margins have expanded from -310.4% to -50.8% over the past 3 years, signaling improving operational efficiency. A negative ROE of -240.1% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 96.5% | 96.5% | 96.1% | 85.2% | 79.7% | -276.7% | — | — | — | — | — |
| Operating Margin | -50.8% | -50.8% | -143.4% | -310.4% | -503.8% | -56678.3% | — | — | — | — | — |
| Net Profit Margin | -52.2% | -52.2% | -150.4% | -327.8% | -527.7% | -57144.5% | — | — | — | — | — |
Return on Capital
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -240.1% | -240.1% | -1035.4% | -215.3% | -5015.4% | -2256.5% | -169.5% | -244.4% | -410.8% | -296.4% | -191.6% |
| ROA | -43.5% | -43.5% | -82.4% | -73.3% | -85.3% | -166.2% | -118.2% | -111.3% | -141.9% | -114.2% | -97.6% |
| ROIC | -608.5% | -608.5% | -543.4% | — | — | — | — | — | — | — | — |
| ROCE | -228.3% | -228.3% | -195.1% | -80.4% | -147.3% | -415.6% | -170.2% | -162.0% | -163.4% | -135.4% | -111.9% |
EVOK Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $14M exceeds total debt of $5M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.73 | 0.73 | — | 1.26 | 1.41 | — | 0.03 | — | — | — | 1.26 |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -1.20 | — | -1.15 | -1.16 | — | -1.26 | -1.32 | -3.55 | -2.38 | -1.24 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -10.38 | -10.38 | -14.86 | -15.57 | -16.30 | -115.47 | — | -526.83 | -1722.76 | -39.34 | — |
Net cash position: cash ($14M) exceeds total debt ($5M)
EVOK Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
A current ratio of 1.66x means Evoke Pharma, Inc. can comfortably meet its short-term obligations, though there is limited excess liquidity. The current ratio has declined from 7.08x to 1.66x over the past 3 years.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.66 | 1.66 | 0.71 | 7.08 | 7.51 | 1.23 | 3.10 | 3.46 | 3.82 | 6.58 | 5.19 |
| Quick Ratio | 1.62 | 1.62 | 0.66 | 6.91 | 7.38 | 1.20 | 3.10 | 3.46 | 3.82 | 6.58 | 5.19 |
| Cash Ratio | 1.31 | 1.31 | 0.49 | 5.95 | 6.51 | 1.07 | 2.81 | 3.25 | 3.70 | 6.38 | 4.74 |
| Asset Turnover | — | 0.59 | 0.73 | 0.21 | 0.15 | 0.00 | — | — | — | — | — |
| Inventory Turnover | 0.80 | 0.80 | 0.42 | 1.28 | 1.77 | 0.37 | — | — | — | — | — |
| Days Sales Outstanding | — | 86.19 | 47.42 | 90.91 | 66.59 | 369.61 | — | — | — | — | — |
EVOK Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Evoke Pharma, Inc. returns 0.0% to shareholders annually primarily through share buybacks.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $2M | $278558 | $261968 | $223512 | $177028 | $154833 | $115294 | $103457 | $64847 | $45040 |
Peer Comparison
Compare EVOK with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 EVOKYou | $19M | -3.9 | — | — | 96.5% | -50.8% | -240.1% | -608.5% | — |
 PRPO | $53M | -10.4 | — | 245.7 | 47.3% | -26.4% | -32.3% | -24.3% | — |
 AYTU | $16M | -1.1 | — | — | 69.0% | -11.8% | -58.1% | -33.5% | — |
 TLSA | $192M | -6.9 | — | — | — | — | -250.5% | -481.7% | — |
 MBRX | $29M | -0.1 | — | — | — | — | -319.8% | -441.5% | — |
 ANIP | $2B | 25.3 | 9.0 | 9.6 | — | 12.6% | 16.2% | 11.2% | 1.6 |
 HROW | $1B | -278.9 | — | — | 75.1% | 11.2% | -8.5% | 9.5% | — |
 PRAX | $10B | -24.7 | — | — | — | — | -45.8% | -65.0% | — |
 LPTX | $65M | 11.0 | — | — | — | — | 16.3% | -48.3% | — |
 NTRB | $46M | -1.5 | — | — | 25.7% | -408.4% | -125.6% | -270.2% | — |
 PAHC | $2B | 36.3 | 15.7 | 41.8 | 30.9% | 8.5% | 17.8% | 9.8% | 4.9 |
| Healthcare Median | — | 22.3 | 14.5 | 18.5 | 64.0% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 14 years · Updated daily
See EVOK's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs EVOK Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare EVOK vs PRPO
Side-by-side business, growth, and profitability comparison vs Precipio, Inc..
Start ComparisonEVOK — Frequently Asked Questions
Quick answers to the most common questions about buying EVOK stock.
What is Evoke Pharma, Inc.'s P/E ratio?
Evoke Pharma, Inc.'s current P/E ratio is -3.9x. This places it at the 50th percentile of its historical range.
What is Evoke Pharma, Inc.'s ROE?
Evoke Pharma, Inc.'s return on equity (ROE) is -240.1%. The historical average is -247.5%.
Is EVOK stock overvalued?
Based on historical data, Evoke Pharma, Inc. is trading at a P/E of -3.9x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Evoke Pharma, Inc.'s profit margins?
Evoke Pharma, Inc. has 96.5% gross margin and -50.8% operating margin.